Air Products expects full-year EPS of $14.15 to $14.50, up 5% to 8%, and CapEx of $3 to $3.5 billion, while its industrial gas backlog reached $3.3 billion.
APD · Air Products & Chemicals, Inc. · Documents
$318.99
+2.46 (+0.78%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q4 2026 earnings call transcript
Market Cap
$70.49B
Shares
222.69M
Volume · Nov 13
651.84K
Avg daily vol (3M)
1.07M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Nov 5
Earnings call
Full-year EPS outlook is $14.15 to $14.50
Nov 5
Current report
8-K
Adjusted EPS rose 12 percent as fiscal 2027 guidance issued
Air Products and Chemicals, Inc. reported fiscal 2026 adjusted EPS of $13.45, up 12 percent, and sales of $13.0 billion. It guided to fiscal 2027 adjusted EPS of $14.15 to $14.50 and capital expenditures of $3.0 billion to $3.5 billion.
Jul 30
Jul 30
Quarterly report
10-Q
FY2026 Q3, ended Jun 30
Quarterly report for FY2026 Q3
AI summary on its way
Revenue $3.16B
▲ 4.6%
Net loss $1.44B
Diluted EPS -$6.47
Jul 30
Jun 30
Current report
8-K
Events of Jun 26
Material impairment, Regulation FD disclosure
AI summary on its way
Apr 30
Apr 30
Quarterly report
10-Q
FY2026 Q2, ended Mar 31
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $3.17B
▲ 8.8%
Net income $710.4M
Diluted EPS $3.19
Apr 30
Jan 30
Jan 30
Jan 30
Quarterly report
10-Q
FY2026 Q1, ended Dec 31
Quarterly report for FY2026 Q1
AI summary on its way
Revenue $3.1B
▲ 5.8%
Net income $678.2M
▲ 9.8%
Diluted EPS $3.04
▲ 9.7%
Jan 29
2025
Dec 11
Proxy statement
DEF 14A
Meeting Jan 28, 2026
Proxy statement
Dec 11
Annual report to holders
ARS
Annual report to holders
Dec 11
Proxy statement
DEFA14A
Proxy statement
Nov 25
Current report
8-K
Events of Nov 23
Director or officer change, or executive pay, Other events
Nov 20
Annual report
10-K
FY2025, ended Sep 30
Annual report for FY2025
Revenue $12.04B
▼ 0.5%
Net loss $394.5M
Diluted EPS -$1.77
Nov 6
Current report
8-K
Financial results
Nov 6
Earnings call
Q4 2025 earnings call
Aug 20
Current report
8-K
Events of Aug 18
Director or officer change, or executive pay
Jul 31
Current report
8-K
Financial results
Jul 31
Quarterly report
10-Q
FY2025 Q3, ended Jun 30
Quarterly report for FY2025 Q3
Revenue $3.02B
▲ 1.2%
Net income $713.8M
▲ 2.5%
Diluted EPS $3.20
▲ 2.2%
Jul 31
Earnings call
Q3 2025 earnings call
Jul 8
Current report
8-K
Events of Jul 7
Director or officer change, or executive pay
Jun 11
Current report
8-K
Events of Jun 9
Other events
May 1
Current report
8-K
Financial results
May 1
Quarterly report
10-Q
FY2025 Q2, ended Mar 31
Quarterly report for FY2025 Q2
Revenue $2.92B
▼ 0.5%
Net loss $1.73B
Diluted EPS -$7.77
May 1
Earnings call
Q2 2025 earnings call
Feb 24
Current report
8-K
Material impairment, Regulation FD disclosure
Feb 13
Current report
8-K
Events of Feb 10
Other events
Feb 6
Current report
8-K
Financial results
Feb 6
Quarterly report
10-Q
FY2025 Q1, ended Dec 31
Quarterly report for FY2025 Q1
Revenue $2.93B
▼ 2.2%
Net income $617.4M
▲ 1.3%
Diluted EPS $2.77
▲ 1.5%
Feb 6
Earnings call
Q1 2025 earnings call
Feb 5
Current report
8-K
Events of Jan 31
Charter or bylaw amendment, or fiscal year change
Feb 4
Current report
8-K
Director or officer change, or executive pay
Jan 27
Current report
8-K
Events of Jan 23
Shareholder vote results
Jan 17
Proxy statement
DEFA14A
Proxy statement
Jan 17
Proxy statement
DEFA14A
Proxy statement
Jan 16
Proxy statement
DEFA14A
Proxy statement
Jan 15
Proxy statement
DEFA14A
Proxy statement
Jan 14
Current report
8-K
Financial results
Jan 14
Proxy statement
DEFA14A
Proxy statement
Jan 14
Proxy statement
DEFA14A
Proxy statement
Jan 14
Proxy statement
DEFA14A
Proxy statement
Jan 13
Proxy statement
DEFA14A
Proxy statement
Jan 13
Proxy statement
DEFA14A
Proxy statement
Jan 10
Proxy statement
DEFA14A
Proxy statement
Jan 10
Proxy statement
DEFA14A
Proxy statement
Jan 8
Proxy statement
DEFA14A
Proxy statement
Showing 1–50 of 175 documents
Key facts
CIK
2969
CUSIP
009158106
13F (30d)
1331 filings
1253 filers
Visit website
Investor relations